Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity
AssigneeRoche Glycart AG
InventorsPablo Umana, Joël Jean-Mairet, James E. Bailey
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity.
Claims31
1-85. (canceled)
A glycoengineered, recombinant antibody comprising an immunoglobulin G (IgG) Fc region containing N-linked oligosaccharides, wherein said antibody is isolated from a mammalian host cell and has been engineered to have an increased proportion of nonfucosylated oligosaccharides in the Fc region compared to the corresponding antibody produced by the same host cell that has not been glycoengineered, and wherein said antibody has increased Fc-mediated cellular cytotoxicity and/or Fc receptor binding affinity as a result of said increased proportion of nonfucosylated, oligosaccharides.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.